On-line Table: Description of patient-specific cases^a

Patient No. (Sex)	Age (yr) at Time of Treatment	Diagnosis	RX (Gy/Fraction)	Time between XRT–V1/V1–V2 (mo)	Current Clinical Status
1 (F)	29	WHO grade II meningioma Rt. sphenoid wing	Operation + 60/30	30/11	Employed part-time August 2015; MRI findings stable; postsurgery changes and post-XRT WM changes
				Both preupgrade	
2 (F)	32	Midline recurrent atypical meningioma	Operation + 66/30	14/X	Stable MRI findings; no evidence of progression; stable residual masses next to treated area
3 (F)	57	WHO grade 1 meningioma occipital region	Operation + 54/30	30/X	Asymptomatic from meningioma; no evidence of recurrence; unrelated thyroid treatment
4 (F)	57	Craniopharyngioma	54/30	13/14	Reduction in size of craniopharyngioma; stable FLAIR hyperintensities in the hippocampi bilaterally
5 (F)	57	Left acoustic neuroma and posterior fossa meningioma	Operation + 54/30	23/10	Working full-time; occasional dizziness bending over or working on ladders; stable right cerebellopontine angle meningioma
				Both preupgrade	
6 (F)	63	Meningioma of the left sphenoid wing	Operation + 66/30	17/22	Retired; well with no symptoms and no evidence of progression/recurrence on MRI
7 (F)	55	Brain stem glioma WHO grade I	54/30	23/22	Elevated prolactin due to pituitary dysfunction; possible treatment effect; some facial twitching like initial presentation of tumor, but not requiring treatment; near-complete response
8 (M)	33	Recurrent meningioma of base of skull	54/30	20/12	Working full-time with mild
				Both preupgrade	fatigue; short-term memory problems; history of WBRT for ALL in 1982
9 (M)	50	Left posterior fossa meningioma	60/30	14/X	Stable on follow-up imaging with decreasing enhancement in cerebellum
10 (F)	45	Left temporal lobe mixed oligoastrocytoma WHO grade II	60/30	14/X	Developed glioblastoma; no follow-up

Note:—VI indicates visit 1; V2, visit 2; RX, treatment; WBRT, whole brain radiotherapy; WHO, World Health Organization; X, patient did not return; Rt., right; ALL, acute lymphocytic leukemia.

^a Their time between XRT, visit 1, visit 2, and their current clinical status.